Guardian Pharmacy Services, Inc. (GRDN)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NYSE
Market Cap: $3.14B
Last updated: Nov 17, 2026 at 11:06 AM ET
Guardian Pharmacy Services, Inc. (GRDN) Financials: Revenue, Profit and Cash Flow
Guardian Pharmacy Services reported revenue of $1.45B for the fiscal year ended Dec 31, 2025, up 17.9% from the year before. That year, net income was $48.96M with a net margin of 3.4%, operating cash flow was $100.25M and free cash flow was $67.29M. The quarter ended Sep 30, 2026 had revenue of $371.07M and net income of $19.12M.
Revenue and Margins
The operating margin was 5.0% in the fiscal year ended Dec 2025. Over the 7 years to Dec 2025, revenue grew from $600.37M, a compound annual rate of 13.4%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1.45B | +17.9% | 20.2% | 5.0% | 3.4% |
| Dec 2024 | $1.23B | +17.4% | 19.9% | -5.1% | -5.8% |
| Dec 2023 | $1.05B | +15.1% | 19.9% | 3.9% | 3.6% |
| Dec 2022 | $908.91M | +14.8% | 20.4% | 5.7% | 3.9% |
| Dec 2021 | $792.07M | +7.6% | 20.4% | 3.8% | 2.1% |
| Dec 2020 | $735.96M | +5.4% | 20.0% | 4.4% | 2.7% |
| Dec 2019 | $698.29M | +16.3% | 20.5% | 4.9% | 3.1% |
| Dec 2018 | $600.37M | N/A | 20.5% | 4.3% | 2.4% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income rose 99.4% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.45B | $1.23B | $1.05B | $908.91M | $792.07M | $735.96M | $698.29M | $600.37M |
| Cost of revenue | $1.16B | $984.04M | $837.88M | $723.04M | $630.81M | $588.96M | $554.83M | $477.33M |
| Gross profit | $292.72M | $244.37M | $208.31M | $185.87M | $161.26M | $147.00M | $143.46M | $123.03M |
| Operating income | $72.70M | -$62.92M | $40.95M | $51.99M | $30.15M | $32.06M | $34.10M | $25.93M |
| Net income | $48.96M | -$71.03M | $37.72M | $35.42M | $16.31M | $19.94M | $21.75M | $14.68M |
| EBITDA | $96.42M | -$43.43M | $58.81M | $68.15M | $46.49M | $49.07M | $49.47M | $38.30M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $371.07M | $351.77M | $336.60M | $397.62M | $377.43M | $344.33M | $329.31M | $338.57M | $314.39M | $300.04M | $275.41M | $281.07M |
| Gross profit | $85.22M | $80.04M | $76.31M | $85.50M | $74.72M | $68.15M | $64.35M | $67.10M | $60.88M | $61.29M | $55.10M | $54.58M |
| Operating income | $25.06M | $20.64M | $17.68M | $30.76M | $16.35M | $12.58M | $13.01M | $16.75M | -$104.61M | $17.00M | $7.93M | $15.52M |
| Net income | $19.12M | $22.12M | $13.54M | $21.27M | $9.59M | $8.83M | $9.27M | $11.84M | -$105.82M | $15.85M | $7.09M | $12.02M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $7.15M by $58.47M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $412.66M | $320.81M | $271.17M | $256.11M | $235.85M | $217.87M | $196.51M | $181.81M |
| Current assets | $221.63M | $151.99M | $129.60M | $120.00M | $111.87M | $93.82M | $90.08M | $81.23M |
| Cash and equivalents | $65.62M | $4.66M | $752.00K | $607.00K | $15.01M | $6.45M | $275.00K | $2.25M |
| Total liabilities | $194.73M | $170.83M | $211.31M | $180.18M | $182.53M | $150.80M | $139.47M | $113.80M |
| Short-term debt | $7.15M | $10.62M | $12.98M | $16.34M | $11.93M | $12.56M | $19.87M | $4.99M |
| Long-term debt | N/A | N/A | $18.99M | $22.97M | $26.99M | $30.74M | N/A | N/A |
| Shareholder equity | $205.76M | $142.67M | $28.21M | $42.73M | $23.93M | $38.48M | $57.04M | $34.03M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $491.78M | $443.58M | $426.94M | $412.66M | $390.04M | $356.33M | $334.00M | $320.81M | $348.03M | $305.12M | N/A | $271.17M |
| Total liabilities | $212.06M | $185.94M | $194.52M | $194.73M | $194.54M | $176.66M | $170.78M | $170.83M | $214.13M | $247.91M | -$59.86M | $211.31M |
| Cash and equivalents | $119.66M | $89.81M | $64.89M | $65.62M | $36.49M | $18.82M | $14.00M | $4.66M | $37.22M | $1.54M | N/A | $752.00K |
| Shareholder equity | $267.24M | $245.61M | $220.89M | $205.76M | $183.76M | $169.56M | $156.09M | $142.67M | $127.57M | $17.88M | $59.86M | $28.21M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 67.1% of operating cash flow. Dividends and share repurchases together came to 46.2% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $100.25M | $57.96M | $70.82M | $48.52M | $58.50M | $52.61M | $56.16M | $43.67M |
| Capital expenditures | $32.96M | $31.08M | $15.54M | $16.77M | $9.28M | $8.34M | $14.54M | $10.01M |
| Free cash flow | $67.29M | $26.88M | $55.28M | $31.75M | $49.22M | $44.27M | $41.62M | $33.67M |
| Dividends paid | $458.00K | $50.21M | $54.90M | $30.80M | $17.36M | $10.82M | $34.32M | $27.99M |
| Share repurchases | $30.63M | $59.33M | $0 | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | -$32.23M | -$30.41M | -$13.44M | -$17.90M | -$13.15M | -$12.18M | -$16.59M | -$20.75M |
| Financing cash flow | -$7.07M | -$23.64M | -$57.23M | -$45.03M | -$36.79M | -$34.26M | -$41.55M | -$21.07M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $43.37M | $30.02M | $6.06M | $34.60M | $28.17M | $19.94M | $17.55M | $22.34M | -$2.16M | $29.13M | $8.65M | $14.55M |
| Capital expenditures | $8.43M | $4.62M | $5.02M | $4.72M | $3.71M | $13.23M | $5.80M | $6.75M | $7.34M | $13.29M | $3.69M | $2.76M |
| Free cash flow | $34.94M | $25.41M | $1.04M | $29.88M | $24.46M | $6.71M | $11.74M | $15.59M | -$9.51M | $15.84M | $4.96M | $11.79M |
Frequently Asked Questions About GRDN
What is Guardian Pharmacy Services' annual revenue?
Guardian Pharmacy Services reported revenue of $1.45B for the fiscal year ended Dec 31, 2025.
How fast is Guardian Pharmacy Services' revenue growing?
Revenue was up 17.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 16.8%.
Is Guardian Pharmacy Services profitable?
Yes. Guardian Pharmacy Services reported net income of $48.96M for the fiscal year ended Dec 31, 2025, with a net margin of 3.4%.
How much free cash flow does GRDN generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $100.25M minus capital expenditures of $32.96M produced free cash flow of $67.29M.
How much debt does Guardian Pharmacy Services have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $7.15M and cash and equivalents of $65.62M.
GRDN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors